Research company Cessatech's US manufacturing partner STAQ Pharma has released the first commercial batch of CT001, a nasal spray containing sufentanil and ketamine for children. This is stated in a press release.The product is thus available for delivery to the first US hospitals, and Cessatech can, together with its partners, begin launch activities at selected hospitals."We are aware that it will take time to establish CT001 on the market, but this milestone provides an important foundation for the work ahead," says Jes Trygved, CEO of Cessatech.